A diagnostics company specializing in genetic testing and precision medicine, Natera provides non-invasive prenatal testing, cancer screening, and organ health monitoring. Its growth potential stems from expanding adoption of cell-free DNA tests in reproductive health and oncology markets.
4 members of Congress have disclosed 8 trades in Natera, Inc. (NTRA), a Healthcare company. The buy/sell breakdown shows 4 purchases versus 4 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-09-22 | Josh Gottheimer | buy | $1K – $15K |
| 2025-08-22 | Josh Gottheimer | buy | $1K – $15K |
| 2025-07-22 | Josh Gottheimer | sell | $1K – $15K |
| 2024-11-20 | Josh Gottheimer | buy | $1K – $15K |
| 2024-08-02 | Rohit Khanna | sell | $1K – $15K |
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2023-03-06 | Daniel Goldman | buy | $1K – $15K |
| 2021-04-20 | William F Hagerty, IV | sell | $1K – $15K |